610 related articles for article (PubMed ID: 28039276)
1. The pharmacodynamics of avibactam in combination with ceftaroline or ceftazidime against β-lactamase-producing Enterobacteriaceae studied in an in vitro model of infection.
MacGowan A; Tomaselli S; Noel A; Bowker K
J Antimicrob Chemother; 2017 Mar; 72(3):762-769. PubMed ID: 28039276
[TBL] [Abstract][Full Text] [Related]
2. Supporting the ceftaroline fosamil/avibactam Enterobacteriaceae breakpoint determination using humanised in vivo exposures in a thigh model.
Bhalodi AA; Crandon JL; Williams G; Nicolau DP
Int J Antimicrob Agents; 2014 Dec; 44(6):508-13. PubMed ID: 25278330
[TBL] [Abstract][Full Text] [Related]
3. Activities of ceftazidime and avibactam against β-lactamase-producing Enterobacteriaceae in a hollow-fiber pharmacodynamic model.
Coleman K; Levasseur P; Girard AM; Borgonovi M; Miossec C; Merdjan H; Drusano G; Shlaes D; Nichols WW
Antimicrob Agents Chemother; 2014 Jun; 58(6):3366-72. PubMed ID: 24687507
[TBL] [Abstract][Full Text] [Related]
4. Ceftazidime/avibactam versus standard-of-care agents against carbapenem-resistant Enterobacteriaceae harbouring blaKPC in a one-compartment pharmacokinetic/pharmacodynamic model.
Barber KE; Pogue JM; Warnock HD; Bonomo RA; Kaye KS
J Antimicrob Chemother; 2018 Sep; 73(9):2405-2410. PubMed ID: 29939267
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic and Pharmacodynamic Analysis of Ceftazidime/Avibactam in Critically Ill Patients.
Stein GE; Smith CL; Scharmen A; Kidd JM; Cooper C; Kuti J; Mitra S; Nicolau DP; Havlichek DH
Surg Infect (Larchmt); 2019 Jan; 20(1):55-61. PubMed ID: 30351195
[TBL] [Abstract][Full Text] [Related]
6. The postantibiotic effect and post-β-lactamase-inhibitor effect of ceftazidime, ceftaroline and aztreonam in combination with avibactam against target Gram-negative bacteria.
Pillar CM; Stoneburner A; Shinabarger DL; Krause KM; Nichols WW
Lett Appl Microbiol; 2016 Aug; 63(2):96-102. PubMed ID: 27221329
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamics of β-lactamase inhibition by NXL104 in combination with ceftaroline: examining organisms with multiple types of β-lactamases.
Louie A; Castanheira M; Liu W; Grasso C; Jones RN; Williams G; Critchley I; Thye D; Brown D; Vanscoy B; Kulawy R; Drusano GL
Antimicrob Agents Chemother; 2012 Jan; 56(1):258-70. PubMed ID: 22024819
[TBL] [Abstract][Full Text] [Related]
8. Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from U.S. hospitals (2011 to 2013) and characterization of β-lactamase-producing strains.
Castanheira M; Mills JC; Costello SE; Jones RN; Sader HS
Antimicrob Agents Chemother; 2015; 59(6):3509-17. PubMed ID: 25845862
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics-Pharmacodynamics of CB-618 in Combination with Cefepime, Ceftazidime, Ceftolozane, or Meropenem: the Pharmacological Basis for a Stand-Alone β-Lactamase Inhibitor.
Ambrose PG; VanScoy BD; Trang M; McCauley-Miller J; Conde H; Bhavnani SM; Alexander DC; Friedrich LV
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28947474
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam.
Singh R; Kim A; Tanudra MA; Harris JJ; McLaughlin RE; Patey S; O'Donnell JP; Bradford PA; Eakin AE
J Antimicrob Chemother; 2015 Sep; 70(9):2618-26. PubMed ID: 26024868
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing
Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F
Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755
[TBL] [Abstract][Full Text] [Related]
12. Activity of Ceftazidime-Avibactam against Extended-Spectrum- and AmpC β-Lactamase-Producing Enterobacteriaceae Collected in the INFORM Global Surveillance Study from 2012 to 2014.
Karlowsky JA; Biedenbach DJ; Kazmierczak KM; Stone GG; Sahm DF
Antimicrob Agents Chemother; 2016 May; 60(5):2849-57. PubMed ID: 26926635
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of a Ceftazidime-Avibactam combination in a murine model of Septicemia caused by Enterobacteriaceae species producing ampc or extended-spectrum β-lactamases.
Levasseur P; Girard AM; Lavallade L; Miossec C; Pace J; Coleman K
Antimicrob Agents Chemother; 2014 Nov; 58(11):6490-5. PubMed ID: 25136016
[TBL] [Abstract][Full Text] [Related]
14. Activity of ceftazidime-avibactam against multidrug-resistance Enterobacteriaceae expressing combined mechanisms of resistance.
López-Hernández I; Alonso N; Fernández-Martínez M; Zamorano L; Rivera A; Oliver A; Conejo MC; Martínez-Martínez L; Navarro F; Pascual A
Enferm Infecc Microbiol Clin; 2017 Oct; 35(8):499-504. PubMed ID: 27887765
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and Efficacy of Ceftazidime-Avibactam in the Treatment of Experimental Pneumonia Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae in Persistently Neutropenic Rabbits.
Petraitiene R; Petraitis V; Kavaliauskas P; Maung BBW; Khan F; Naing E; Aung T; Zigmantaite V; Grigaleviciute R; Kucinskas A; Stakauskas R; Georgiades BN; Mazur CA; Hayden JA; Satlin MJ; Walsh TJ
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015048
[No Abstract] [Full Text] [Related]
16. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae.
Aktaş Z; Kayacan C; Oncul O
Int J Antimicrob Agents; 2012 Jan; 39(1):86-9. PubMed ID: 22041508
[TBL] [Abstract][Full Text] [Related]
17. A novel mechanism-based pharmacokinetic-pharmacodynamic (PKPD) model describing ceftazidime/avibactam efficacy against β-lactamase-producing Gram-negative bacteria.
Kristoffersson AN; Bissantz C; Okujava R; Haldimann A; Walter I; Shi T; Zampaloni C; Nielsen EI
J Antimicrob Chemother; 2020 Feb; 75(2):400-408. PubMed ID: 31670804
[TBL] [Abstract][Full Text] [Related]
18. In vitro antibacterial activity of the ceftazidime-avibactam combination against enterobacteriaceae, including strains with well-characterized β-lactamases.
Levasseur P; Girard AM; Miossec C; Pace J; Coleman K
Antimicrob Agents Chemother; 2015 Apr; 59(4):1931-4. PubMed ID: 25583732
[TBL] [Abstract][Full Text] [Related]
19. Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals.
Castanheira M; Doyle TB; Deshpande LM; Mendes RE; Sader HS
Int J Antimicrob Agents; 2021 Nov; 58(5):106439. PubMed ID: 34547421
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of ceftazidime/avibactam against urinary isolates from patients in a Phase 3 clinical trial programme for the treatment of complicated urinary tract infections.
Stone GG; Bradford PA; Yates K; Newell P
J Antimicrob Chemother; 2017 May; 72(5):1396-1399. PubMed ID: 28088768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
